Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials
暂无分享,去创建一个
Gianni Tognoni | M. Roncaglioni | J. Berger | David L. Brown | G. Tognoni | F. Avanzini | Jeffrey S Berger | David L Brown | R. Odouli | I. Pangrazzi | Maria C Roncaglioni | Fausto Avanzini | Ierta Pangrazzi | David L Brown | J. Berger | De-Kun Li | Jeffrey S. Berger | Diana B. Petitti | Jeffrey S Berger | Fausto Avanzini | Gianni Tognoni | David L Brown | David L Brown | Gianni Tognoni | David L Brown | Gianni Tognoni | Marian Willinger | Liyan Liu | Howard J Hoffman | Gianni Tognoni | David L Brown
[1] Constance K Haan,et al. Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women , 2004, Circulation.
[2] M. Roncaglioni. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general Practice , 2001, The Lancet.
[3] R. J. Hayes,et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.
[4] B. Weksler,et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. , 1983, The New England journal of medicine.
[5] R. Doll,et al. Randomised trial of prophylactic daily aspirin in British male doctors , 1988, British medical journal.
[6] E. Topol,et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. , 2001, The American journal of cardiology.
[7] P. Ridker,et al. Anti-Platelet Effects of 100 mg Alternate Day Oral Aspirin: A Randomized, Double-Blind, Placebo-Controlled Trial of Regular and Enteric Coated Formulations in Men and Women , 1996, Journal of cardiovascular risk.
[8] W. Richardson,et al. Selecting and Appraising Studies for a Systematic Review , 1997, Annals of Internal Medicine.
[9] Final report on the aspirin component of the ongoing Physicians' Health Study. , 1989, The New England journal of medicine.
[10] M. Harrison,et al. A Sex Difference in the Effect of Aspirin on “Spontaneous” Platelet Aggregation in Whole Blood , 1983, Thrombosis and Haemostasis.
[11] C. Hennekens,et al. An update on aspirin in the primary prevention of cardiovascular disease. , 2003, Archives of internal medicine.
[12] M. Roizen. Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-analysis of Randomized Controlled Trials , 2007 .
[13] Walker,et al. Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .
[14] James F Sallis,et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. , 2002, Circulation.
[15] G. Mancia,et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. , 1998, Atherosclerosis.
[16] Constance K Haan,et al. Evidence-based guidelines for cardiovascular disease prevention in women. , 2004, Circulation.
[17] P. Nihoyannopoulos,et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. , 1999, Circulation.
[18] P. Ridker,et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.
[19] Ian Graham,et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. , 1998, European heart journal.
[20] Joël Ménard,et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.
[21] M. Harrison,et al. Sex difference in antithrombotic effect of aspirin. , 1989, Stroke.
[22] G. FitzGerald,et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.
[23] D. Thompson. Review: aspirin was effective for primary prevention of stroke in women and MI in men but increased major bleeding , 2006, Evidence-based nursing.
[24] U. P. S. T. Force,et al. Measuring Quality: Are We Ready To Compare the Quality of Care among Physician Groups? , 2002, Annals of Internal Medicine.
[25] C. Patrono,et al. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. , 1982, The Journal of clinical investigation.
[26] A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women , 2005 .
[27] Catherine Sudlow,et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.
[28] G. Davı̀,et al. Clinical pharmacology of platelet cyclooxygenase inhibition. , 1985, Circulation.
[29] G. Escolar,et al. Sex-related differences in the effects of aspirin on the interaction of platelets with subendothelium. , 1986, Thrombosis research.
[30] S. Yusuf,et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. , 2005, JAMA.